D. Yocum

Addressing the Pilot security problem with gLExec (2008)

I Sfiligoi, O Koeroo, G Venekamp, D Yocum, D Groep, D Petravick

Abstract. The Grid security mechanisms were designed under the assumption that users would submit their jobs directly to the Grid gatekeepers. Many groups are however starting to use pilot-based...

Standardizing Assessment and Reporting of Adverse Effects in Rheumatology Clinical Trials II: the Rheumatology Common Toxicity Criteria v.2.0 (2007)

Woodworth, T, Furst, DE, Alten, R, Bingham, C, Yocum, D, Sloan, V, ...

Objective. The OMERACT Drug Safety Working Group focuses on standardization of assessment and reporting of adverse events in clinical trials and longitudinal and observational studies in...

Standardizing Assessment and Reporting of Adverse Effects in Rheumatology Clinical Trials II: the Rheumatology Common Toxicity Criteria v.2.0 (2007)

Woodworth, T, Furst, DE, Alten, R, Bingham, C, Yocum, D, Sloan, V, ...

Objective. The OMERACT Drug Safety Working Group focuses on standardization of assessment and reporting of adverse events in clinical trials and longitudinal and observational studies in...

The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: A large, randomized, placebo-controlled trial (2006)

Westhovens, R., Yocum, D., Han, J., Berman, A., Strusberg, I., ...

OBJECTIVE: To assess the risk of serious infections following 22 weeks of infliximab therapy, and to further characterize the safety profile of infliximab in combination with background treatments...

The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: A large, randomized, placebo-controlled trial (2006)

Westhovens, R., Yocum, D., Han, J., Berman, A., Strusberg, I., ...

OBJECTIVE: To assess the risk of serious infections following 22 weeks of infliximab therapy, and to further characterize the safety profile of infliximab in combination with background treatments...

The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: A large, randomized, placebo-controlled trial (2006)

Westhovens, R., Yocum, D., Han, J., Berman, A., Strusberg, I., GEUSENS, Piet, ...

OBJECTIVE: To assess the risk of serious infections following 22 weeks of infliximab therapy, and to further characterize the safety profile of infliximab in combination with background treatments...

The safety and efficacy of infliximab in RA: 1-year results of a large, randomized, placebo-controlled trial in patients with various comorbidities and background treatments as encountered in clinical practice. (2004)

Yocum, D, Wolfe, F, Rahman, MU, Han, J, Berman, A, Strusberg, I, ...

Univ Arizona, Tucson, AZ USA. Natl Data Bank Rheum Dis, Wichita, KS USA. Centocor Inc, Malvern, PA 19355 USA. Hosp Angel C Padilla, San Miguel De Tucuman, Argentina. Ctr Reumatol Strusberg, Cordoba,...

The safety and efficacy of infliximab in RA: 1-year results of a large, randomized, placebo-controlled trial in patients with various comorbidities and background treatments as encountered in clinical practice. (2004)

Yocum, D, Wolfe, F, Rahman, MU, Han, J, Berman, A, Strusberg, I, ...

Univ Arizona, Tucson, AZ USA. Natl Data Bank Rheum Dis, Wichita, KS USA. Centocor Inc, Malvern, PA 19355 USA. Hosp Angel C Padilla, San Miguel De Tucuman, Argentina. Ctr Reumatol Strusberg, Cordoba,...

Measurement of the mass difference m(D-s(+))-m(D+) at CDF II (2003)

Acosta, D., Affolder, T., Ahn, M. H., Akimoto, T., Albrow, M. G., Alcorn, B., ...

We present a measurement of the mass difference m(D-s(+))-m(D+), where both the D-s(+) and D+ are reconstructed in the phipi(+) decay channel. This measurement uses 11.6 pb(-1) of data collected by...

Measurement of the mass difference m(D-s(+))-m(D+) at CDF II (2003)

CDF Collaboration, Acosta, D, Affolder, T, Ahn, MH, Akimoto, T, Albrow, MG, ...

New and future drug therapies for rheumatoid arthritis (2000)

Simon, L.S., Yocum, D.

Neutron spectroscopy of high-density amorphous ice (1999)

Kolesnikov, A I, Li, J-C, Ahmad, NC, Loong, C-K, Nipko, J, Yocum, D, ...

Immunological actions of cyclosporin A in rheumatoid arthritis (1993)

Yocum, D